Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other financing activities (2016 - 2025)

United Therapeutics' Other financing activities history spans 16 years, with the latest figure at $11.5 million for Q2 2025.

  • For Q2 2025, Other financing activities changed N/A year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, up 325.93%, while the annual FY2025 figure was $11.5 million, 325.93% up from the prior year.
  • Other financing activities for Q2 2025 was $11.5 million at United Therapeutics, up from $2.7 million in the prior quarter.
  • Across five years, Other financing activities topped out at $11.5 million in Q2 2025 and bottomed at $2.7 million in Q1 2023.
  • The 4-year median for Other financing activities is $5.1 million (2022), against an average of $6.1 million.
  • The largest annual shift saw Other financing activities plummeted 64.0% in 2023 before it changed 0.0% in 2024.
  • A 4-year view of Other financing activities shows it stood at $7.5 million in 2022, then tumbled by 64.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then surged by 325.93% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Other financing activities are $11.5 million (Q2 2025), $2.7 million (Q1 2024), and $2.7 million (Q1 2023).